Role of immunosuppressive drugs for prevention of graft-v-host disease after bone marrow transplantation.
In a series of 198 patients we compared various methods of prevention of GVHD. One hundred and thirty-three patients were treated with CSA alone, 44 with the combination of CSA and MTX, and 21 with CSA after marrow T cell depletion. The incidence of GVHD greater than or equal to II was 35% in the CSA group, 22% in the CSA+MTX group and 14% in the T depleted group. The actuarial survival was 55.4%, 52.3% and 55.1% respectively. These results show that the improvement of methods of prevention of GVHD did not affect significantly long term survival after BMT.
Devergie
A
A
Hôpital Saint-Louis, Unité Fonctionelle de Greffe de Moelle, Paris, France.
Esperou
H
H
Traineau
R
R
Varrin
F
F
Lehn
P
P
Gluckman
E
E
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D003524:Cyclosporins / Q000627:therapeutic use*; D004341:Drug Evaluation; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008212:Lymphocyte Depletion; D008727:Methotrexate / Q000627:therapeutic use*; D011897:Random Allocation
D003524:Cyclosporins; D007166:Immunosuppressive Agents; D008727:Methotrexate